Ablation as First-Line Therapy for Atrial Fibrillation: Yes

Pasquale Santangeli, Luigi Di Biase, Amin Al-Ahmad, Rodney Horton, J. David Burkhardt, Javier E. Sanchez, G. Joseph Gallinghouse, Jason Zagrodzky, Rong Bai, Agnes Pump, Sanghamitra Mohanty, William R. Lewis, Andrea Natale

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


This article addresses the use of catheter ablation (CA) as first-line therapy for atrial fibrillation (AF). CA increases long-term freedom from AF, reduces hospitalizations, and improves quality of life compared with antiarrhythmic drug (AAD) therapy in patients with symptomatic AF who have already failed one AAD. The role of CA as first-line therapy for AF, however, is still controversial. Evidence from randomized controlled trials shows that CA is definitely superior to AADs as first-line therapy for relatively young patients with paroxysmal AF, with comparable complication rates and results consistently reproducible across different institutions, operators, and types of ablation approaches.

Original languageEnglish (US)
Pages (from-to)287-297
Number of pages11
JournalCardiac Electrophysiology Clinics
Issue number3
StatePublished - Sep 2012
Externally publishedYes


  • Atrial fibrillation
  • Catheter ablation
  • First-line therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Ablation as First-Line Therapy for Atrial Fibrillation: Yes'. Together they form a unique fingerprint.

Cite this